On April 9, 2021 Repertoire Immune Medicines, a clinical-stage biotech company decoding the immune synapse to create novel immune therapies for cancer, immune disorders, infectious disease, and other serious diseases, reported the presentation of translational data obtained from applying its proprietary antigen-specific TCR-MHC DECODE platform in its Phase 1 trial evaluating PRIME IL-15 (RPTR-147) in patients with advanced or metastatic solid tumor cancers (Press release, Repertoire, APR 9, 2021, View Source;-PRIME-IL-15-RPTR-147—-in-Advanced-or-Metastatic-Solid-Tumor-Cancers [SID1234577805]). The data will be presented at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Virtual Meeting Week 1, taking place April 10-15, 2021. PRIME IL-15, the company’s lead investigational therapy, is a novel non-genetically modified, autologous, multiclonal T cell product derived from the patient’s T cell repertoire in the peripheral blood, activated against a curated set of tumor antigens, and armored with an IL-15Fc nanogel. It is being evaluated for a variety of solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In this study, Repertoire Immune Medicines’ applied its proprietary DNA-barcoded pMHC tetramer technology (CIPHERTM) to determine the specificity of its multiclonal T cell product. In addition, bulk sequencing of TCRVβ was performed on tumors pre- and post-treatment and identified product derived CD8+ T cell clonotypes in the post-, but not pre-treatment biopsies. The presentation also details the use of the company’s platform to de-orphan these tumor infiltrating lymphocytes (TIL) of interest, and clone selected TIL TCRs to determine their exact specificities by epitope and HLA.

These translational data demonstrate that rare T cell clones — derived from the peripheral blood — can be amplified and directed to tumor antigens in humans. Further, these findings highlight the unique capability of the company’s DECODE platform to fully decipher the immune synapse by identifying the T cell clones and their cognate antigens by HLA that matter in patients.

Details:

Abstract title: Tracking and Decoding the Antigen Specificity of Peripherally Derived T Cells that Infiltrate into Solid Tumors in patients treated with PRIME IL-15 (RPTR-147)
Session category: Adoptive Cell Therapy (PO.CL06.01)
Date & time: April 10, 2021 from 8:30 a.m. – 12:00 p.m. EDT